Navigation Links
N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
Date:5/5/2008

BOULDER, Colo., May 5 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase I study of N30-201 in patients with mild to moderate asthma, as well as healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.

"We are pleased to have completed the Phase 1 set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to asthmatic, as well as healthy human subjects, is an important step." commented Charles Scoggin, M.D., Chairman of N30 Pharma.

The primary endpoint of the study is patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201, including effects on the airway.

About N30-201

N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a critical store of nitric oxide (NO) bioactivity in the human airway.

About N30 Pharma

N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory and cardiovascular diseases. S-nitrosothiols are endogenous molecules which store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone. N30's drug development strategy focuses on administration of GSNO to the human airway, and the development of inhibitors of GSNO reductase. GSNO reductase is the key enzyme in the body that breaks down GSNO. These approaches allow N30 to deliver targeted, long lasting, physiologically relevant doses of s-nitrosothiols to target systems. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
2. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
5. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
10. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CAMBRIDGE, Mass. , Feb. 27, 2017  Infinity ... presenting at the Cowen and Company 37 th ... 4:00 p.m. ET in Boston, MA. ... accessible on the Investors/Media section of Infinity,s website at ... days following the event. About Infinity,Infinity is ...
(Date:2/27/2017)... February 27, 2017 Now in its ... companies that are most successful at developing and commercialising innovation. ... The ... the same molecule to two different companies in early phase, ... on systematic, objective analysis of each company,s performance between 2011 and 2016, ...
(Date:2/27/2017)... Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... Craig , M.D., Ph.D., as President and Chief Executive Officer ... 20, 2017. Dr. Craig succeeds Richard Love , interim ... company,s Board of Directors.  Dr. Craig has over 20 years ... the US and Europe . ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre ... Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of ... showcases the Centre's commitment to innovation in drug rehab and alcohol treatment strategies ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an innovative ... it would be offering some it’s exclusive product line to the public through ... unique baby clothing/feeding products, will team up with AMAZON to distribute a limited ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging ... according to a study released today at the 1st Pan American Parkinson’s and ... proven to be effective in improving cognitive function in PD patients. This study, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... at his office, Antoine Dental Center. Currently, patients can get single dental implants ... apply, but patients can learn more about these offers by contacting Antoine Dental ...
Breaking Medicine News(10 mins):